Horn D, Neofytos D, Fishman J, Steinbach W, Anaisie E, Marr K A, Pfaller M, Olyaei A
Division of Infectious Diseases, Thomas Jefferson University Hospital, 211 South 9th Street, Philadelphia, PA 19107, USA.
Eur J Clin Microbiol Infect Dis. 2007 Dec;26(12):907-14. doi: 10.1007/s10096-007-0383-4.
Candidemia is an increasing complication of the care of complex patients. Adherence to Infectious Diseases Society of America (IDSA) guidelines for the treatment of candidemia was investigated to assess the impact of compliance on outcomes of therapy. Data on the epidemiology, diagnosis, and treatment of patients with invasive fungal infections (IFIs) was extracted from the PATH Alliance registry, a prospective, multicenter, observational database of invasive fungal infections. Patients with proven candidemia were evaluated for adherence to the IDSA guidelines in terms of choice, dosage, and duration of antifungal therapy. Removal of central venous catheters and time to treatment initiation were assessed. Four-week survival data were compared. Of the 418 patients with candidemia who were included in the study, 361 patients with the necessary data sets were identified, of whom 262 (72.6%) were treated within the IDSA guidelines for the treatment of candidemia (IDSA group); the remaining 99 (27.4%) patients received treatment different from the guidelines (non-IDSA group). Kaplan-Meier (KM) survival analysis for patients in the IDSA and non-IDSA group showed mortality rates of 21.9 and 13.6%, respectively; the difference between the two groups was not statistically significant (P = 0.093). Following the exclusion of patients requiring mechanical ventilation or acute cardiac support, the modified survival KM curves were similar between the two groups. Significantly more patients in the IDSA group required mechanical ventilation and tunneled central catheters, had a concomitant IFI, and received caspofungin. The duration of treatment and inappropriate dosing did not appear to have had a significant impact on survival. Most of the deviations from IDSA guidelines were due to the inappropriate duration and dosing of therapy. No significant difference in mortality was noted between the IDSA and non-IDSA groups. The basis of these differences merit further study.
念珠菌血症是复杂患者护理中日益常见的并发症。本研究调查了对美国感染病学会(IDSA)念珠菌血症治疗指南的依从性,以评估依从性对治疗结果的影响。从PATH联盟登记处提取了侵袭性真菌感染(IFI)患者的流行病学、诊断和治疗数据,该登记处是一个关于侵袭性真菌感染的前瞻性、多中心观察数据库。对确诊念珠菌血症的患者,从抗真菌治疗的选择、剂量和疗程方面评估其对IDSA指南的依从性。评估了中心静脉导管的拔除情况和开始治疗的时间。比较了四周生存率数据。在纳入研究的418例念珠菌血症患者中,确定了361例有必要数据集的患者,其中262例(72.6%)按照IDSA念珠菌血症治疗指南接受治疗(IDSA组);其余99例(27.4%)患者接受了与指南不同的治疗(非IDSA组)。IDSA组和非IDSA组患者的Kaplan-Meier(KM)生存分析显示死亡率分别为21.9%和13.6%;两组之间的差异无统计学意义(P = 0.093)。在排除需要机械通气或急性心脏支持的患者后,两组的改良生存KM曲线相似。IDSA组中需要机械通气和隧道式中心导管的患者明显更多,伴有IFI,且接受了卡泊芬净治疗。治疗持续时间和剂量不当似乎对生存率没有显著影响。大多数与IDSA指南的偏差是由于治疗持续时间和剂量不当。IDSA组和非IDSA组之间的死亡率没有显著差异。这些差异的原因值得进一步研究。